

L1 161479 S ZINC OXIDE OR ZNO
 L2 42106 S (CALCIUM CHANNEL) (2A) (ANTAGONIST# OR BLOCK? OR INHIBIT?)
 L3 51277 S NORVASC OR AMLODIPINE OR PLENDIL OR FELODIPINE OR CARDIZEM OR
 L4 39855 S ADALAT OR PROCARDIA OR NIFEDIPINE OR CARDENE OR NICARDIPINE O
 L5 100876 S L2 OR L3 OR L4
 L6 13 S L1 AND L5
 L7 9 DUP REM L6 (4 DUPLICATES REMOVED)

=> d que

L1 161479 SEA ZINC OXIDE OR ZNO
 L2 42106 SEA (CALCIUM CHANNEL) (2A) (ANTAGONIST# OR BLOCK? OR INHIBIT?)
 L3 51277 SEA NORVASC OR AMLODIPINE OR PLENDIL OR FELODIPINE OR CARDIZEM
 OR DILACOR OR DILTIAZEM OR TIAZAC OR CALAN OR COVERA OR
 ISOPTIN OR VERELAN OR VERAPAMIL
 L4 39855 SEA ADALAT OR PROCARDIA OR NIFEDIPINE OR CARDENE OR NICARDIPINE
 OR SULAR OR NISOLDIPINE OR VASCOR OR BEPRIDIL OR MIBEFRADIL
 OR POSICOR
 L5 100876 SEA L2 OR L3 OR L4
 L6 13 SEA L1 AND L5
 L7 9 DUP REM L6 (4 DUPLICATES REMOVED)

=> d 1-9 bib ab kwic; file stnguide

L7 ANSWER 1 OF 9 HCAPLUS COPYRIGHT 2005 ACS on STN DUPLICATE 1
 AN 2005:1892 HCAPLUS
 DN 142:100379
 TI Antibacterial/antifungal wound healing compositions for mammals
 IN Peshoff, Mickey L.
 PA USA
 SO U.S. Pat. Appl. Publ., 23 pp., Cont.-in-part of U.S. Ser. No. 125,165.
 CODEN: USXXCO
 DT Patent
 LA English
 FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004265396	A1	20041230	US 2003-675729	20030930
	US 2002114847	A1	20020822	US 2002-125165	20020418
	US 6660306	B2	20031209		
PRAI	US 2000-689087	B2	20001012		
	US 2002-125165	A2	20020418		
AB	This invention pertains to therapeutic antibacterial/antifungal-wound healing comps. comprising a therapeutically effective amount of antibacterial agents and/or antifungal agents and/or wound healing composition alone. In one embodiment, the wound healing composition comprises (a) zinc oxide ; (b) calcium channel blocker , and (c) fat-soluble vitamins admixed with antibacterial and antifungal agents. The therapeutic antibacterial/antifungal-wound healing comps. may be utilized in a wide variety of pharmaceutical products and administered orally or topically.				
AB	This invention pertains to therapeutic antibacterial/antifungal-wound healing comps. comprising a therapeutically effective amount of antibacterial agents and/or antifungal agents and/or wound healing composition alone. In one embodiment, the wound healing composition comprises (a) zinc oxide ; (b) calcium channel blocker , and (c) fat-soluble vitamins admixed with antibacterial and antifungal agents. The therapeutic antibacterial/antifungal-wound healing comps. may be utilized in a wide variety of pharmaceutical products and administered orally or topically.				
IT	50-14-6, Ergocalciferol 56-75-7, Chloramphenicol 57-62-5, Chlortetracycline 57-92-1, Streptomycin, biological studies 58-95-7, Vitamin e acetate 59-87-0, Nitrofurazone 60-54-8, Tetracycline 60-54-8D, Tetracycline, derivs. 61-33-6, Penicillin G, biological studies 65-85-0, Benzoic acid, biological studies 67-20-9, Nitrofurantoin 67-45-8, Furazolidone 67-97-0, Cholecalciferol				

68-26-8, Retinol 69-53-4, Ampicillin 79-57-2, Oxytetracycline
 79-80-1 79-81-2, Retinyl palmitate 87-08-1, Penicillin V 99-26-3,
 Bismuth subgallate 114-07-8, Erythromycin 153-61-7, Cephalothin
 432-70-2, α -Carotene 443-48-1, Metronidazole 472-92-4,
 δ -Carotene 472-93-5, γ -Carotene 564-25-0, Doxycycline
 1314-13-2, **Zinc oxide**, biological studies 1344-85-0,
 Bismuth aluminate 1403-66-3, Gentamycin 1404-04-2, Neomycin
 1405-87-4, Bacitracin 1405-89-6, Zinc bacitracin 1406-05-9, Penicillin
 1406-11-7, Polymixin 1406-16-2, Vitamin D 1406-18-4, Vitamin E
 6506-37-2, Nimorazole 6998-60-3, Rifamycin 7235-40-7, β -Carotene
 8063-07-8, Kanamycin 11103-57-4, Vitamin A 11111-12-9, Cephalosporin
 12001-79-5, Vitamin K 13292-46-1, Rifampin 14882-18-9, Bismuth
 subsalicylate 15686-71-2, Cephalexin 18323-44-9, Clindamycin
 19387-91-8, Tinidazole 21829-25-4 23593-75-1, Clotrimazole
 26787-78-0, Amoxicillin 27220-47-9, Econazole 37311-39-0, Vitamin e
 succinate 57644-54-9, Bismuth subcitrate 61318-90-9, Sulconazole
 64211-45-6, Oxiconazole 65277-42-1, Ketoconazole 68844-77-9,
 Astemizole 71276-50-1, Vitamin E phosphate 73590-58-6, Omeprazole
 84625-61-6, Itraconazole 86386-73-4, Fluconazole 91161-71-6,
 Terbinafine
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (antibacterial/antifungal wound healing compns. for mammals)

L7 ANSWER 2 OF 9 HCAPLUS COPYRIGHT 2005 ACS on STN DUPLICATE 2
 AN 2004:802266 HCAPLUS
 DN 141:301527
 TI Compositions and kits for compounding pharmaceuticals
 IN Muni, Indu A.
 PA Cutispharma, Inc., USA
 SO U.S. Pat. Appl. Publ., 24 pp., Cont.-in-part of U.S. Ser. No. 707,783.
 CODEN: USXXCO

DT Patent
 LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004191276	A1	20040930	US 2004-787546	20040226
	US 6708822	B1	20040323	US 2000-707783	20001107
PRAI	US 1999-168168P	P	19991130		
	US 2000-707783	A2	20001107		

AB The invention provides compns. and methods for the convenient compounding of pharmaceuticals. Single and multiple unit of use kits are provided which contain all the necessary components required for preparing a compounded pharmaceutical. For example, the kit FIRxST used for compounding hydrocortisone in ultrasound gel was able to reduce the air bubbles and keep the uniformity of the composition by adding simethicone (anti-foaming) and PEG.

IT 50-02-2, Dexamethasone 50-23-7, Hydrocortisone 50-24-8, Prednisolone
 50-27-1, Estriol 50-28-2, Estradiol, biological studies 50-48-6,
 Amitriptyline 51-34-3, Scopolamine 51-42-3, Epinephrine bitartrate
 51-43-4, Adrenaline 51-48-9, Levothyroxine, biological studies
 51-55-8, Atropine, biological studies 52-53-9, **Verapamil**
 53-16-7, Estrone, biological studies 53-86-1, Indomethacin 55-31-2,
 Epinephrine hydrochloride 55-63-0, Nitroglycerin 56-75-7,
 Chloramphenicol 57-27-2, Morphine, biological studies 57-83-0,
 Progesterone, biological studies 57-85-2, Testosterone propionate
 58-00-4, Apomorphine 58-22-0, Testosterone 58-33-3, Promethazine
 hydrochloride 59-66-5, Acetazolamide 60-56-0, Methimazole 60-87-7,
 Promethazine 63-42-3, Lactose 68-04-2, Sodium citrate 68-35-9,
 Sulfadiazine 69-72-7, Salicylic acid, biological studies 73-78-9,
 Lidocaine hydrochloride 76-25-5, Triamcinolone acetonide 80-08-0,
 Dapsone 86-22-6, Brompheniramine 89-57-6, Mesalamine 94-13-3, Propyl
 paraben 99-76-3, Methyl paraben 100-51-6, Benzyl alcohol, biological
 studies 110-27-0, Isopropyl myristate 110-44-1, Sorbic acid
 124-94-7, Triamcinolone 127-08-2, Potassium acetate 127-31-1,
 Fludrocortisone 128-37-0, Butylated hydroxytoluene, biological studies
 136-47-0 142-91-6, Isopropyl palmitate 144-55-8, Sodium bicarbonate,
 biological studies 147-24-0, Benadryl 298-46-4, 5H-Dibenz[b,f]azepine-

5-carboxamide 315-30-0, Allopurinol 439-14-5, Diazepam 443-48-1,
 Metronidazole 446-86-6, Azathioprine 525-66-6, Propranolol 616-91-1,
 Acetylcysteine 674-38-4, Bethanechol 866-84-2, Potassium citrate
 1134-47-0, Baclofen 1314-13-2, **Zinc oxide**,
 biological studies 1400-61-9, Nystatin 1406-18-4, Vitamin E
 2022-85-7, Flucytosine 6740-88-1, Ketamine 7647-15-6, Sodium bromide,
 biological studies 7758-02-3, Potassium bromide, biological studies
 8050-81-5, Simethicone 8055-33-2, Estradiol-testosterone mixture
 8060-43-3 10043-35-3, Boric acid, biological studies 11041-12-6,
 Cholestyramine 13292-46-1, Rifampin 14455-29-9, Aluminum carbonate
 15307-86-5, Diclofenac 15687-27-1, Ibuprofen 22071-15-4, Ketoprofen
 24634-61-5, Potassium sorbate 25322-68-3, PEG 29122-68-7, Atenolol
 32222-06-3, Calcitriol 37317-08-1, Maalox 54143-55-4, Flecainide
 62571-86-2, Captopril 65296-29-9 73590-58-6, Omeprazole 75847-73-3,
 Enalapril 79275-73-3 81098-60-4, Cisapride 82410-32-0, Ganciclovir
 85721-33-1, Ciprofloxacin 86386-73-4, Fluconazole 98443-65-3, Actigel
 763123-29-1 763123-31-5 763123-33-7 763123-34-8 763123-36-0
 763123-38-2 763123-39-3 763123-40-6 763123-41-7 763123-42-8
 763123-43-9 763123-44-0 763123-45-1 763123-46-2 763123-47-3
 763123-48-4

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (FIRxST kits for better compounding pharmaceuticals)

L7 ANSWER 3 OF 9 HCAPLUS COPYRIGHT 2005 ACS on STN

AN 2004:1007932 HCAPLUS

DN 142:246136

TI Multi-component medical preparation for treating hemorrhoid and anal cleft

IN Chen, Guanrong; Liu, Zhong; Huang, Liping; Song, Hongping; Ping, Chengbin

PA Wuhan No.4 Hospital, Peop. Rep. China

SO Faming Zhuanli Shenqing Gongkai Shuomingshu, 8 pp.

CODEN: CNXXEV

DT Patent

LA Chinese

FAN. CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	CN 1470236	A	20040128	CN 2002-138836	20020726
PRAI	CN 2002-138836		20020726		

AB The medical preparation (such as suppository, cream, ointment, gel, oil preparation, lotion, suspension, spray, topical-use solution, or paste) is composed of astringent protectant 0.5-10, disinfection antiseptic 0.2-5, Ca²⁺ antagonist 0.1-5, and carrier to 100%. The astringent protectant is allantoin or its Al salt, **ZnO**, dioctahedral montmorillonite, or their medical salt. The disinfection antiseptic is chlorhexidine acetate, chlorhexidine HCl, etc. The Ca²⁺ antagonist is **nifedipine**, nimodipine, **nicardipine**, nitrendipine, **felodipine**, **diltiazem**, or their medical salt. The carrier is semi-synthetic fatty acid ester, polyethylene glycol, cocoa butter, lanolin, vaseline, propanediol, ointment substrate, etc.

AB The medical preparation (such as suppository, cream, ointment, gel, oil preparation, lotion, suspension, spray, topical-use solution, or paste) is composed of astringent protectant 0.5-10, disinfection antiseptic 0.2-5, Ca²⁺ antagonist 0.1-5, and carrier to 100%. The astringent protectant is allantoin or its Al salt, **ZnO**, dioctahedral montmorillonite, or their medical salt. The disinfection antiseptic is chlorhexidine acetate, chlorhexidine HCl, etc. The Ca²⁺ antagonist is **nifedipine**, nimodipine, **nicardipine**, nitrendipine, **felodipine**, **diltiazem**, or their medical salt. The carrier is semi-synthetic fatty acid ester, polyethylene glycol, cocoa butter, lanolin, vaseline, propanediol, ointment substrate, etc.

IT 56-95-1, Chlorhexidine acetate 97-59-6, Allantoin 3697-42-5,
 Chlorhexidine hydrochloride 21829-25-4, **Nifedipine**
 25322-68-3, Polyethylene glycol 26264-14-2, Propanediol 39562-70-4,
 Nitrendipine 42399-41-7, **Diltiazem** 55985-32-5,
Nicardipine 66085-59-4, Nimodipine 72509-76-3,
Felodipine

RL: PEP (Physical, engineering or chemical process); PYP (Physical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process);

USES (Uses)

(multi-component medical preparation for treating hemorrhoid and anal cleft)

L7 ANSWER 4 OF 9 HCAPLUS COPYRIGHT 2005 ACS on STN

AN 2003:154225 HCAPLUS

DN 138:210299

TI Mucoadhesive erodible drug delivery device for controlled administration of pharmaceuticals and other active compounds

IN Moro, Daniel G.; Callahan, Howard; Nowotnik, David P.

PA Access Pharmaceuticals, Inc., USA

SO PCT Int. Appl., 46 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003015748	A2	20030227	WO 2002-US26083	20020816
	WO 2003015748	A3	20031204		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2003044446	A1	20030306	US 2001-931319	20010816
	US 6585997	B2	20030701		
	EP 1418889	A2	20040519	EP 2002-761390	20020816
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
	JP 2005504763	T2	20050217	JP 2003-520708	20020816
PRAI	US 2001-931319	A	20010816		
	WO 2002-US26083	W	20020816		

AB The present invention relates to a layered pharmaceutical delivery device for the administration of pharmaceuticals or other active compds. to mucosal surfaces. The device may also be used by itself without the incorporation of a therapeutic. The device of the present invention consists of a water-soluble adhesive layer, a non-adhesive, bioerodible backing layer and one or more pharmaceuticals if desired in either or both layers. Upon application, the device adheres to the mucosal surface, providing protection to the treatment site and localized drug delivery. The "Residence Time", the length of time the device remains on the mucosal surface before complete erosion, can be easily regulated by modifications of the backing layer.

IT 50-02-2, Dexamethasone 50-03-3, Hydrocortisone acetate 50-23-7, Hydrocortisone 50-24-8, Prednisolone 50-28-2, Estradiol, biological studies 50-33-9, Phenylbutazone, biological studies 50-59-9, Cefaloridine 50-78-2, Aspirin 52-21-1, Prednisolone acetate 52-26-6, Morphine hydrochloride 53-16-7, Estrone, biological studies 53-86-1, Indomethacin 54-64-8, Thimerosal 55-56-1, Chlorhexidine 56-25-7, Cantharidin 56-75-7, Chloramphenicol 56-81-5, Glycerine, biological studies 57-55-6, Propylene glycol, biological studies 57-62-5, Chlortetracycline 57-92-1, Streptomycin, biological studies 58-22-0, Testosterone 58-33-3, Promethazine hydrochloride 59-87-0, Nitrofurazone 60-54-8, Tetracycline 61-12-1, Dibucaine hydrochloride 61-32-5, Meticillin 61-68-7, Mefenamic acid 61-76-7, Phenylephrine hydrochloride 63-74-1, Sulfamine 65-85-0, Benzoic acid, biological studies 66-79-5, Oxacillin 67-73-2, Fluocinolone acetonide 68-35-9, Sulfadiazine 68-41-7, Cycloserine 69-72-7, Salicylic acid, biological studies 69-81-8, Carbazochrome 72-14-0, Sulfathiazole 73-78-9, Lidocaine hydrochloride 76-25-5, Triamcinolone acetonide 77-07-6, Levorphanol 79-11-8, Chloroacetic acid, biological studies 79-14-1, Glycolic acid, biological studies 79-57-2, Oxytetracycline 83-43-2, Methylprednisolone 84-80-0, Phytonadione 85-79-0, Dibucaine 87-28-5,

Monoglycol salicylate 89-83-8, Thymol 94-09-7, Benzocaine 97-53-0,
 Eugenol 103-90-2, Acetaminophen 108-95-2, Phenol, biological studies
 113-92-8, Chlorpheniramine maleate 114-07-8, Erythromycin 119-36-8,
 Methyl salicylate 123-03-5, Cetylpyridinium chloride 127-69-5,
 Sulfisoxazole 129-20-4, Oxyphenbutazone 137-58-6, Lidocaine
 138-37-4, Homosulfamine 144-82-1, Sulfamethizole 147-24-0,
 Diphenhydramine hydrochloride 153-18-4, Rutin 153-61-7, Cefalotin
 154-21-2, Lincomycin 154-69-8, Tripeleminamine hydrochloride 359-83-1,
 Pentazocine 378-44-9, Betamethasone 426-13-1, Fluorometholone
 437-38-7, Fentanyl 474-86-2, Equilin 515-64-0, Sulfisomidine
 518-28-5, Podofilox 520-26-3, Hesperidin 522-48-5, Tetrahydrozoline
 hydrochloride 530-78-9, Flufenamic acid 532-32-1, Sodium benzoate
 536-43-6, Dyclonine hydrochloride 586-60-7, Dyclonine 1177-87-3,
 Dexamethasone acetate 1197-18-8, Tranexamic acid 1225-60-1,
 Isothipendyl hydrochloride 1229-35-2, Methdilazine hydrochloride
 1314-13-2, **Zinc oxide**, biological studies 1319-82-0,
 Aminocaproic acid 1403-66-3, Gentamicin 1405-87-4, Bacitracin
 1406-05-9, Penicillin 1420-53-7, Codeine sulfate 1605-68-1, Taxane
 2135-17-3, Flumetasone 2152-44-5, Betamethasone valerate 2315-02-8,
 Oxymetazoline hydrochloride 2438-72-4, Bufenamac 2840-24-6,
 Trimethylammonium bromide 3540-95-2, Fenpiprane 3715-90-0,
 Tramazolinehydrochloride 5104-49-4, Flurbiprofen 5144-52-5,
 Naphazoline nitrate 5534-09-8 7440-06-4D, Platinum, compds.
 7761-88-8, Silver nitrate, biological studies 8063-07-8, Kanamycin
 9000-65-1, Tragacanth gum 9002-04-4, Thrombin 9002-72-6, Somatotropin
 9002-89-5, Polyvinyl alcohol 9003-01-4, Polyacrylic acid 9003-39-8,
 Polyvinyl pyrrolidone 9004-32-4, Carboxymethyl cellulose 9004-57-3,
 Ethyl cellulose 9004-61-9, Hyaluronic acid 9004-62-0, Hydroxyethyl
 cellulose 9004-64-2, Hydroxypropyl cellulose 9004-65-3, Hydroxypropyl
 methylcellulose 9004-67-5, Methylcellulose 9005-38-3, Sodium alginate
 10101-52-7, Zirconium silicate 13463-67-7, Titanium dioxide, biological
 studies 15307-79-6, Diclofenac sodium 15307-86-5, Diclofenac
 15687-27-1, Ibuprofen 16110-51-3, Cromolyn 16488-48-5 17449-96-6,
 Clofezone 18046-21-4, Fentiazac 18323-44-9, Clindamycin 18694-40-1,
 Mepirizole 21829-25-4, **Nifedipine** 22071-15-4, Ketoprofen
 22131-79-9, Alclofenac 22204-53-1, Naproxen 24561-10-2, Piperocaine
 hydrochloride 25322-68-3, Polyethylene glycol 25655-41-8, Povidone
 iodine 29122-68-7, Atenolol 29679-58-1, Fenoprofen 34148-01-1,
 Clidanac 34645-84-6, Fenclofenac 35941-71-0, Tiaramide hydrochloride
 36322-90-4, Piroxicam 37205-61-1, Protease inhibitor 38194-50-2,
 Sulindac 39809-25-1, Penciclovir 51110-01-1, Somatostatin
 51460-26-5, Carbazochrome sodium sulfonate 52485-79-7, Buprenorphine
 52549-17-4, Pranoprofen 53902-12-8, Tranilast 57775-29-8, Carazolol
 58581-89-8, Azelastine 59277-89-3, Acyclovir 64706-54-3,
Bepridil 68302-57-8, Amlexanox 68844-77-9, Astemizole
 69372-19-6, PEmirolast 73080-51-0, Repirinast 82410-32-0, Ganciclovir
 83150-76-9, Octreotide 86880-51-5, Epanolol 124832-26-4, Valacyclovir
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (mucoadhesive erodible drug delivery device for controlled
 administration of pharmaceuticals and other active compds.)

L7 ANSWER 5 OF 9 HCAPLUS COPYRIGHT 2005 ACS on STN DUPLICATE 3
 AN 2001:78273 HCAPLUS
 DN 134:136717
 TI Preserved pharmaceutical formulations containing benzethonium chloride
 IN Gayed, Atef
 PA Aventis Pharmaceuticals, Inc., USA
 SO PCT Int. Appl., 35 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001007086	A1	20010201	WO 2000-US20040	20000721
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA,				

MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI,
SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM,
AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ,
CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

CA 2378892 AA 20010201 CA 2000-2378892 20000721
EP 1200128 A1 20020502 EP 2000-948895 20000721
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL
BR 2000012674 A 20020917 BR 2000-12674 20000721
EE 200200038 A 20030415 EE 2002-38 20000721
JP 2003520777 T2 20030708 JP 2001-511969 20000721
NZ 516736 A 20040227 NZ 2000-516736 20000721
AU 777410 B2 20041014 AU 2000-62325 20000721
NO 2002000304 A 20020321 NO 2002-304 20020121
ZA 2002000743 A 20030429 ZA 2002-743 20020128
PRAI US 1999-228815P P 19990722
US 1999-359063 A1 19990722
WO 2000-US20040 W 20000721

AB The present invention is directed to the use of the benzethonium chloride,
alone or in combination with phenoxyethanol or phenylethyl alc., to
provide antimicrobial activity in pharmaceutical compns. The present
invention also provides methods of using benzethonium chloride, alone or
in combination with phenoxyethanol or phenylethyl alc., to inhibit
microbial growth in pharmaceutical compns. A composition was prepared containing
fexofenadine, xylitol, sorbitol, glycerin, Na saccharin, benzethonium
chloride, phenoxyethanol, and NaOH was prepared

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

IT 50-06-6, Phenobarbital, biological studies 50-78-2, Aspirin 51-34-3,
Scopolamine 51-61-6, Dopamine, biological studies 52-53-9,
Verapamil 54-31-9, Furosemide 56-81-5, Glycerol, biological
studies 57-27-2, Morphine, biological studies 57-41-0, Phenytoin
58-55-9, Theophylline, biological studies 58-73-1, Diphenhydramine
60-54-8, Tetracycline 68-88-2, Hydroxyzine 72-44-6, Methaqualone
83-67-0, Theobromine 114-07-8, Erythromycin 137-58-6, Lidocaine
317-34-0, Aminophylline 564-25-0, Doxycycline 614-39-1, Procainamide
hydrochloride 630-93-3, Dilantin 1314-13-2, **Zinc**
oxide, biological studies 1404-04-2, Neomycin 1406-05-9,
Penicillin 2609-46-3, Amiloride 8063-07-8, Kanamycin 9001-62-1,
Lipase 9002-01-1, Streptokinase 9005-49-6, Heparin, biological studies
9006-65-9, Dimethicone 9039-53-6, Urokinase 20830-75-5, Digoxin
26787-78-0, Amoxycillin 42399-41-7, **Diltiazem** 59865-13-3,
Cyclosporine 66357-35-5, Ranitidine 70458-96-7, Norfloxacin
75330-75-5, Lovastatin 83799-24-0, Fexofenadine 139639-23-9, Tissue
plasminogen activator

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(preserved pharmaceutical formulations containing benzethonium chloride)

L7 ANSWER 6 OF 9 HCAPLUS COPYRIGHT 2005 ACS on STN
AN 2000:585801 HCAPLUS
DN 133:155469
TI Antihypertensive ointment
IN Wang, Debo
PA Peop. Rep. China
SO Faming Zhuanli Shenqing Gongkai Shuomingshu, 9 pp.
CODEN: CNXXEV

DT Patent
LA Chinese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	CN 1222377	A	19990714	CN 1998-110018	19980108
	CN 1061256	B	20010131		
PRAI	CN 1998-110018		19980108		

AB An antihypertensive ointment for external use is composed of traditional
Chinese medicine extract 20-30, **nifedipine** 35-45, **ZnO** as

photoprotective agent 6-10, Azone 11-18, methylsilicone oil as release-sustained agent 8.4-14%, excipients and water. The ointment may also contain 1.8-3.0% stabilizers. The traditional Chinese medicine extract is manufactured from ramuli et spina uncariae 35-55, Apocynum venetum 15-25, chrysanthemum 15-25, radix salivae miltiorrhizae 15-25, Na benzoate 0.2-0.4, and/or chlorhexidine acetate 0.2-0.4%, and prepared by mixing, boiling, and filtering.

AB An antihypertensive ointment for external use is composed of traditional Chinese medicine extract 20-30, **nifedipine** 35-45, **ZnO** as photoprotective agent 6-10, Azone 11-18, methylsilicone oil as release-sustained agent 8.4-14%, excipients and water. The ointment may also contain 1.8-3.0% stabilizers. The traditional Chinese medicine extract is manufactured from ramuli et spina uncariae 35-55, Apocynum venetum 15-25, chrysanthemum 15-25, radix salivae miltiorrhizae 15-25, Na benzoate 0.2-0.4, and/or chlorhexidine acetate 0.2-0.4%, and prepared by mixing, boiling, and filtering.

ST antihypertensive ointment Chinese medicine **nifedipine**

IT 56-95-1, Chlorhexidine acetate 532-32-1, Sodium benzoate 1314-13-2,

Zinc oxide, biological studies 21829-25-4,

Nifedipine 59227-89-3, Azone

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(antihypertensive ointment)

L7 ANSWER 7 OF 9 HCAPLUS COPYRIGHT 2005 ACS on STN

AN 1993:154582 HCAPLUS

DN 118:154582

TI Solid pharmaceutical compositions for oral administration with prolonged gastric residence

IN Esposito, Pierandrea; Carli, Fabio

PA Vectorpharma International S.p.A., Italy

SO Eur. Pat. Appl., 20 pp.

CODEN: EPXXDW

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 526862	A1	19930210	EP 1992-113187	19920803
	EP 526862	B1	19960214		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
	AT 134134	E	19960215	AT 1992-113187	19920803
	ES 2086029	T3	19960616	ES 1992-113187	19920803
PRAI	IT 1991-MI2212	A	19910806		

AB The title compns. comprise an active ingredient characterized by erratic gastrointestinal absorption, a high d. inorg. substance, such as BaSO₄, Fe, Mg trisilicate, and a bioadhesive polymer, such as cellulose ethers and acrylate copolymers. For example, a tablet was formulated containing **nifedipine** with micronized crosslinked PVP (1:5) 240, BaSO₄ 235, Methocel A4C 155, Aerosil 200 5, xanthan gum 30, galactomannan 30, and Mg stearate 5 mg.

AB The title compns. comprise an active ingredient characterized by erratic gastrointestinal absorption, a high d. inorg. substance, such as BaSO₄, Fe, Mg trisilicate, and a bioadhesive polymer, such as cellulose ethers and acrylate copolymers. For example, a tablet was formulated containing **nifedipine** with micronized crosslinked PVP (1:5) 240, BaSO₄ 235, Methocel A4C 155, Aerosil 200 5, xanthan gum 30, galactomannan 30, and Mg stearate 5 mg.

ST tablet stomach bioadhesive inorg compd; **nifedipine** cellulose barium sulfate tablet

IT 50-78-2, Acetylsalicylic acid 51-06-9, Procainamide 51-21-8, 5-Fluorouracil 52-53-9, **Verapamil** 53-86-1, Indomethacin 55-63-0, Nitroglycerin 56-54-2, Quinidine 57-22-7, Vincristine 57-41-0, Phenytoin 58-55-9, Theophylline, biological studies 58-73-1, Diphenhydramine 58-94-6, Chlorothiazide 59-63-2, Isocarboxazide 59-92-7, Dopa, biological studies 60-54-8, Tetracycline 60-87-7, Promethazine 68-19-9, Cyanocobalamin 69-53-4, Ampicillin 71-58-9, Medroxyprogesterone acetate 82-92-8, Cyclizine 83-88-5, Riboflavin, biological studies 86-54-4, Hydralazine 91-81-6 113-92-8,

Chlorpheniramine maleate 114-07-8, Erythromycin 298-57-7, Cinnarizine 317-34-0 471-34-1, Calcium carbonate, biological studies 521-78-8, Trimipramine maleate 525-66-6 546-93-0, Magnesium carbonate 595-33-5, Megestrol acetate 637-07-0, Clofibrate 652-67-5, Isosorbide 768-94-5, Amantadine 846-49-1, Lorazepam 846-50-4, Temazepam 1225-55-4, Protriptyline hydrochloride 1305-78-8, Calcium oxide, biological studies 1309-37-1, Ferric oxide, biological studies 1309-42-8, Magnesium hydroxide 1309-48-4, Magnesium oxide (MgO), biological studies 1314-13-2, **Zinc oxide**, biological studies 1327-39-5, Calcium aluminum silicate 1327-43-1 1335-30-4 1344-28-1, Aluminum oxide, biological studies 1345-25-1, Ferrous oxide, biological studies 1402-38-6, Actinomycin 1622-62-4, Flunitrazepam 1951-25-3, Amiodarone 5697-56-3 7439-89-6, Iron, biological studies 7727-43-7, Barium sulfate 7757-93-9, Calcium dibasic phosphate 7758-23-8, Calcium monobasic phosphate 7778-18-9, Calcium sulfate 10103-46-5, Calcium phosphate 10361-44-1, Bismuth nitrate 11113-52-3, Calcium ferrite 12060-58-1, Samarium oxide 12061-16-4, Erbium oxide 13463-67-7, Titania, biological studies 13523-86-9, Pindolol 14646-16-3, Erbium hydroxide 14987-04-3, Magnesium trisilicate 15687-27-1 16508-95-5, Bismuth carbonate 18559-94-9, Salbutamol 20830-81-3, Daunorubicin 21645-51-2, Aluminum hydroxide, biological studies 21829-25-4, **Nifedipine** 22071-15-4 22204-53-1, Naproxen 23031-25-6, Terbutaline 23214-92-8, Adriamycin 25953-19-9 26787-78-0, Amoxycillin 26839-75-8, Timolol 27848-84-6, Nicergoline 29767-20-2, Teniposide 30516-87-1, Zidovudine 33419-42-0, Etoposide 34866-47-2, Carbuterol 36322-90-4, Piroxicam 38194-50-2, Sulindac 39377-59-8, Samarium hydroxide 42200-33-9, Nadolol 42399-41-7, **Diltiazem** 51022-70-9, Salbutamol sulfate 51384-51-1, Metoprolol 51481-61-9, Cimetidine 53164-05-9 54182-58-0 57808-66-9, Domperidone 59277-89-3, Acyclovir 59338-93-1, Alizapride 66357-35-5, Ranitidine 73384-59-5, Ceftriaxone 73590-58-6 75847-73-3, Enalapril 76596-57-1 82410-32-0, Gancyclovir

RL: BIOL (Biological study)

(oral solid pharmaceuticals with prolonged gastric residence containing)

L7 ANSWER 8 OF 9 HCAPLUS COPYRIGHT 2005 ACS on STN DUPLICATE 4
 AN 1990:104868 HCAPLUS
 DN 112:104868
 TI Controlled release drug dosage form
 IN Samejima, Masayoshi; Noda, Kazuo; Kobayashi, Masao; Ishikawa, Shigeyuki
 PA Tanabe Seiyaku Co., Ltd., Japan
 SO Eur. Pat. Appl., 21 pp.
 CODEN: EPXXDW
 DT Patent
 LA English
 FAN. CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 315414	A1	19890510	EP 1988-310271	19881101
	EP 315414	B1	19911016		
	R: AT, BE, CH, DE, ES, GB, GR, IT, LI, LU, NL, SE				
	IL 88083	A1	19921115	IL 1988-88083	19881019
	ZA 8808147	A	19900627	ZA 1988-8147	19881031
	JP 01230513	A2	19890914	JP 1988-277631	19881101
	JP 07000552	B4	19950111		
	AT 68343	E	19911115	AT 1988-310271	19881101
	ES 2027013	T3	19920516	ES 1988-310271	19881101
	CA 1331565	A1	19940823	CA 1988-582132	19881103
	DK 8806180	A	19890507	DK 1988-6180	19881104
	DK 175249	B1	20040719		
	FI 8805101	A	19890507	FI 1988-5101	19881104
	FI 96273	B	19960229		
	FI 96273	C	19960610		
	NO 8804947	A	19890508	NO 1988-4947	19881104
	NO 176233	B	19941121		
	NO 176233	C	19950301		
	AU 8824727	A1	19890511	AU 1988-24727	19881104
	AU 610275	B2	19910516		

FR 2622799	A1	19890512	FR 1988-14466	19881104
FR 2622799	B1	19911129		
HU 50624	A2	19900328	HU 1988-5710	19881104
HU 201468	B	19901128		
US 4963365	A	19901016	US 1988-267085	19881104
SU 1816213	A3	19930515	SU 1988-4356826	19881104
CN 1033007	A	19890524	CN 1988-107687	19881105
CN 1035099	B	19970611		
PRAI JP 1987-281189	A	19871106		
EP 1988-310271	A	19881101		

AB A controlled-release dosage form consists of a core containing a medicament, an inner coating layer composed of ethyl cellulose and a hydrophobic substance, and an outer coating layer containing a medicament. The dosage form shows rapid increase in blood concentration of the medicament and maintains a high level of the blood concentration over a prolonged period time. Nonpareil (trade name) sucrose particles (800 g) were coated with 3200 g **diltiazem**-HCl, 267 g talc and 3520 g PVP (in EtOH), to give a core. An inner coating layer of 1.5% by weight ethyl cellulose and 7.6% talc (referred to the core) was applied to the core, followed by application of 6.9% **diltiazem**-HCl. In-vitro tests indicated that the dissoln. rate may be controlled by adjusting the coating amts. of the inner layer.

AB A controlled-release dosage form consists of a core containing a medicament, an inner coating layer composed of ethyl cellulose and a hydrophobic substance, and an outer coating layer containing a medicament. The dosage form shows rapid increase in blood concentration of the medicament and maintains a high level of the blood concentration over a prolonged period time. Nonpareil (trade name) sucrose particles (800 g) were coated with 3200 g **diltiazem**-HCl, 267 g talc and 3520 g PVP (in EtOH), to give a core. An inner coating layer of 1.5% by weight ethyl cellulose and 7.6% talc (referred to the core) was applied to the core, followed by application of 6.9% **diltiazem**-HCl. In-vitro tests indicated that the dissoln. rate may be controlled by adjusting the coating amts. of the inner layer.

IT 50-70-4, Sorbitol, biological studies 57-11-4D, Stearic acid, salts with alkaline-earth metals 57-50-1, biological studies 58-55-9, biological studies 63-42-3, Lactose 69-65-8, Mannitol 471-34-1, Calcium carbonate, biological studies 1314-13-2, **Zinc oxide**, biological studies 7631-86-9, Silica, biological studies 9004-57-3, Ethyl cellulose 13463-67-7, Titanium oxide, biological studies 14807-96-6, Talc, biological studies 25322-68-3
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (pharmaceuticals containing, sustained-release)

IT 33286-22-5, **Diltiazem** hydrochloride
 RL: BIOL (Biological study)
 (sustained-release formulation of)

L7 ANSWER 9 OF 9 HCAPLUS COPYRIGHT 2005 ACS on STN

AN 1986:230479 HCAPLUS

DN 104:230479

TI Transdermal tapes containing **nifedipine**

IN Ito, Toshio

PA Nichiban Co., Ltd., Japan

SO Jpn. Kokai Tokkyo Koho, 4 pp.

CODEN: JKXXAF

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 61018717	A2	19860127	JP 1984-137985	19840705
PRAI	JP 1984-137985		19840705		

AB Pharmaceutical transdermal tapes contain **nifedipine** dissolved in iso-Pr myristate and/or iso-Pr lanolin esters and an adhesive layer. The transdermal administration produces less side effects than the oral formulations. Thus, Na acrylate polymer 50, carboxyvinyl polymer 30, CM-cellulose 20, glycerin 200, TiO₂ 20, **ZnO** 20, kaolin clay 100, H₃PO₄ 10, and polyoxyethylene sorbitan monooleate 5 g were mixed, and 400 g H₂O was slowly added. To this was added 10 g **nifedipine** dissolved in 40 g Me Et ketone, followed 90 g iso-Pr lanolin. The mixture

was made into a gel sheet and laminated with an acrylic polymer adhesive.

TI Transdermal tapes containing **nifedipine**

AB Pharmaceutical transdermal tapes contain **nifedipine** dissolved in iso-Pr myristate and/or iso-Pr lanolin esters and an adhesive layer. The transdermal administration produces less side effects than the oral formulations. Thus, Na acrylate polymer 50, carboxyvinyl polymer 30, CM-cellulose 20, glycerin 200, TiO₂ 20, **ZnO** 20, kaolin clay 100, H₃PO₄ 10, and polyoxyethylene sorbitan monooleate 5 g were mixed, and 400 g H₂O was slowly added. To this was added 10 g **nifedipine** dissolved in 40 g Me Et ketone, followed 90 g iso-Pr lanolin. The mixture was made into a gel sheet and laminated with an acrylic polymer adhesive.

ST **nifedipine** isopropyl myristate pharmaceutical tape

IT Fatty acids, esters

RL: BIOL (Biological study)

(lanolin, esters with, pharmaceutical transdermal tapes containing **nifedipine** and)

IT 110-27-0

RL: BIOL (Biological study)

(pharmaceutical transdermal tapes containing **nifedipine** and)